WHAT IS CLAIMED IS:

1. Use of COR-001 for the manufacture of a medicament for reducing the risk of cardiovascular morbidity and mortality in a patient with inflammation that has KDOQI stage 3-5 chronic kidney disease and a CRP level greater than 2 mg/L, wherein COR-001 is administered at a dose of 5-30 mg subcutaneously once a month, wherein the dose is sufficient to reduce the CRP level to 2 mg/L or less and does not cause a decrease in absolute neutrophil count (ANC) below 1,500 cells/µL.

2. Use of COR-001 according to claim 1, wherein COR-001 is administered at a dose of 10-20 mg subcutaneously once a month.

3. Use of COR-001 according to claim 1, wherein COR-001 is administered at a dose of 15 mg subcutaneously once a month.

4. Use of COR-001 according to any one of claims 1 to 3, wherein the administration reduces the risk of heart failure and/or cardiovascular death.

5. Use of COR-001 according to any one of claims 1 to 3, wherein the cardiovascular morbidity and mortality is selected from a group consisting of (i) nonfatal myocardial infarction, (ii) nonfatal stroke, and (iii) cardiovascular death.

6. Use of COR-001 according to any one of claims 1 to 3, wherein the cardiovascular morbidity and mortality is heart failure.